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INTRODUCTION
Retinoids are one of the most extensively studied agents in the secondary and tertiary chemoprevention of lung cancer. A common problem with these chemicals is pan-retinoid toxicity, yet numerous natural and synthetic retinoids-effective inhibitors of tumor cell growth in vitro and in vivo and selective for the different retinoid receptor isotopes-have been generated that circumvent pan-retinoid toxicity. The tumor-suppressive activity of selective retinoids and rexinoids have been established preclinically, and emerging clinical trials are supportive of the chemotherapeutic and chemopreventive potential of these compounds in multiple oncological indications, with reduced toxicity. 1 One recent chemopreventive trial, which randomized former smokers to 13cRA plus α-tocopherol, 9cRA, or placebo in an attempt to reverse premalignant lesions with the desired biomarker, retinoic acid receptor-β (RAR-β), being upregulated in bronchial epithelium, showed that administration of 9cRA decreased the percentage of subjects with detectable squamous metaplasia in biopsy sites and increased RAR-β expression. 2 Although RAR-β is effectively upregulated by 9cRA in bronchial epithelium, data implicating maintenance of RAR-β intratumorly in NSCLC patients showed a poorer prognosis have cast RAR-β in a less favorable light. 1, 3 Retinoid refractoriness, in terms of inducing RAR-β expression or apoptosis with treatment of retinoids, is attributable, at least partially, to aberrant promoter methylation and histone H3 acetylation. One study showed retinoid receptor function to be intact in the t-RA-refractory malignant HBE cell line, however, suggesting that the defect in retinoid signaling in this lung carcinogenesis model was not intrinsic to the retinoid receptors. 4 Such findings indicate the urgent need to discover a cellular mediator of chemoprevention of retinoic acids other than RAR-β.
Insulin-like growth factor (IGF) binding proteins (IGFBPs), composed of 216 to 289 amino acids and representing a major reservoir of circulating IGFs, mobilize IGFs to peripheral tissues and regulate their biologic activities. 5 IGFBP-1, -2 and -4 traverse the endothelial barrier and carry IGFs into peripheral tissues. Whereas IGFBP-3, the most abundant such binding protein in circulation, can reach 150 kD when bound to IGF-I, cannot penetrate endothelial cells, and has been implicated in regulating the content of IGFs in circulation. 5, 6 IGFBP-3 regulates IGF-1 bioactivity by sequestering IGF-1 away from its receptor in the extracellular milieu, thereby inhibiting the critical role of IGFs in cellular growth, differentiation, transformation, and apoptosis. 5, 7, 8 Besides its IGF-I-dependent function, IGFBP-3, like IGFBP-1 and IGFBP-5, has IGF-I-independent anti-proliferative and pro-apoptotic effects. 9 The bioactivity of IGF system is modulated by retinoids, which not only decreases directly the level of IGF-1 10 but also increases IGFBP-3. 11,12 IGFBP-3, in turn, mediates a wide variety of growth suppression signals, including retinoic acid. Several findings further suggest that IGFBP-3 might be a good candidate as a surrogate marker of chemoprevention. These include a negative correlation between serum IGFBP-3 levels and various solid cancer risks; 13 an association between expression of IGFBP-3 and prognosis of stage I NSCLC patients; 14, 15 and a protective role of IGFBP-3 against the effects of systemic IGF-I, 8 which has been implicated in the development of lung cancer. Thus, an urgent need exists for an effective modality inducing IGFBP-3 expression. The chemotherapeutic and chemopreventive potentials of retinoids and rexinoids might also originate, in part, from induction of IGFBP-3. 16 Yet the mechanism by which IGFBP-3 gene transcription is stimulated by retinoic acids has not been well-studied.
It is known that transcriptional activation by retinoids is mediated through two families of nuclear hormone receptors, the retinoic acid receptors, the RARs and the retinoid X receptors (RXRs). Three distinct RXR and RAR genes have been identified, and, of these nuclear hormone receptors, RAR-β is considered to be a tumor suppressor gene in NSCLC. [17] [18] [19] The retinoic acid receptors are ligand-dependent transcription factors that bind to cis-acting DNA sequences called retinoic acid responsive elements (RAREs) and retinoid X responsive elements (RXREs), located in the promoter region of their target genes. 20 In this study, we report that IGFBP-3 gene expression by 9cRA involves RAR-β and is mediated by a distinct DR-8 responsive element located in the proximal region of the IGFBP-3 promoter.
MATERIALS AND METHODS
Chemicals, cell culture and treatment
, anti-β-actin antibody and other chemicals were obtained from the Sigma Chemical Company (St. Louis, MO, USA) unless otherwise stated. Anti-IGFBP-3, anti-RAR-β, and anti-RXR-β antibodies and siRNA for RAR-β were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Stealth TM RNAi Negative Control Duplexes, lipofectamine TM 2000 were purchased from Invitrogen (Carlsbad CA, USA). Human NSCLC cell lines used in this study (NCI-H596,-A549, -H460, -H1299 and COS7) were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS; Life Technologies, Inc., Gaithersburg, MD, USA). For treatment of each retinoic acid derivative, cells were maintained prior to harvest by splitting and incubation in RPMI-1640 medium supplemented with 2% FCS. To determine the effects of 9cRA on NSCLC cell proliferation, the NSCLC cell lines were plated at concentrations of 1 X 10 3 cells per well in 96-well plates. The next day, cells were treated with various titers of 9cRA and then incubated in 2% RPMI-1640 medium for the assay period. At the end of the assay period, the proliferation of treated cells was measured by using the MTT assay, as previously described elsewhere. Six replicate wells were used for each assay; data from replicate wells are presented as mean values with 95% confidence intervals (CIs). Three independent experiments were performed with similar results; representative results of one experiment are presented.
Soft agar colony formation assay. A colony formation assay was done using 24-well plates. Each well contained 1 mL of 0.5% agar in RPMI-1640 medium supplemented with 2% FCS as the bottom layer, 1 mL of 0.35% agar in 2% RPMI-1640 medium and 3,000 cells as the top layer with or without 500 nM 9cRA. Cultures were maintained under standard culture conditions. The number of colonies was determined with an inverted phase-contrast microscope at X 100 magnification; a group of >10 cells was counted as a colony. The data are means ± SE of four independent wells at optimum time of 14 days after the start of cell seeding.
Analysis of gene expression. Western blot analysis was performed by the standard procedure, employing antibodies raised against human RAR-β, human IGFBP-3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and β-actin (Sigma). For detection of the intended protein, 30 to 50 µg of total protein was size fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions, transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA), and blocked with 5% nonfat dry milk in Tris-buffered saline-Tween (20 mM Tris HCl, pH 7.6; 150 mM NaCl; 0.1% Tween-20). Membranes were incubated with primary antibodies (Santa Cruz Biotechnology) overnight at 4˚C and then with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology) for 1 hr at room temperature. Immunoreactive proteins were detected using an enhanced chemiluminescence (ECL) kit and Hyperfilm ECL (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA). Relative amounts of the proteins of interest were determined using the ScionImage ® software.
RNA preparation and semi-quantitative RT-PCR. Total cellular RNA, isolated from NSCLC cells using TRIzol (Invitrogen), was reverse transcribed and amplified using gene-specific primers and the Superscript TM One-Step RT-PCR System with Platinum TM TaqDNA Polymerase Plasmid preparation. A 1.9-kb IGFBP-3 promoter and its deletion mutants pGL2-∆1600 and pGL2-∆1675, subcloned to the luciferase reporter vector pGL2-basic (Promega Corp., Madison, WI, USA), were generous gifts from Dr. Oh Y (Oregon Health & Science University, Portland, OR, USA). Reporter vector nomenclature, which specifies the number of nucleotides removed from the 5'-end of pGL2-IGFBP-3, was adopted from Walker et al. 21 pGL2-∆862 was prepared from an oligo corresponding to nucleotides -1064 to -64 (relative to the translation start site designated +1) of the IGFBP-3 promoter generated by PCR with the following primers: sense, 5'-GAG ATA AGC TTG AAT CCC AAC GC-3'; anti-sense, 5'-GCG AAG CTT TGG AAT CCA GGC A-3'. The same method was used to prepare pGL2-∆1393 (-534 to -64; sense primer, 5-GTA TGC AAG CTT CCC CGA CAC C-3'; anti-sense primer, 5'-GCG AAG CTT TGG AAT CCA GGC A-3') and pGL2-∆1482 (-445 to -64; sense primer, 5'-GGT GCA AGC TTG GCC AGG AGT-3'; anti-sense primer, 5'-GCG AAG CTT TGG AAT CCA GGC A-3'). Oligos were subcloned into the HindIII site of the pGL2-Basic vector.
pGL2-∆1393 was used as a single-stranded DNA template for the production of mutant pGL2-∆1393(R) with the primer AAG GGG TAA GGG CGG CGG AAA AAA GGA GAT CGG GGG TG and its reverse sequence. pGL2-∆1393(F) was generated using CAC CCC GAG AGC GGA AGA AAA AAG GGC GGC GGG GTC AA-5' and its reverse sequence. pGL2-∆1393(B) was generated using pGL2-∆1393(R) and the same primer set as for pGL2-∆1393(F). pcDNA™3.1D/V5-His-TOPO ® was purchased from Invitrogen, and a full-length cDNA encoding RAR-β was inserted according to the manufacturer's instructions with the following primers: or siRNA for RAR-β in serum-free RPMI-1640 medium. After 6 hr, the medium was changed to RPMI-1640 supplemented with 10% FCS. Cell lysates were collected for luciferase assay 48 hr after transfection. Transfections were performed in triplicate and experiments repeated at least three times. Luciferase activity was measured according to the manufacturer's instructions (Promega) and normalized against β-gal activity.
Electrophoretic mobility shift assay. Three doublestranded 28-mer pairs (bp -488 to -461 from mRNA cap site), corresponding to wild-or mutant-type RARE, were synthesized by Genotech, Inc. (Daejun, Korea). The wildtype oligomer consisted of 5'-GAA GGG GTA AGG GCG GCG GGG TCA AGG A -3' and its reverse complement, while the mutant-type was 5'-GAA GAA AAA AGG GCG GCG AAA AAA AGG A-3' and its reverse complement. These oligomers were end-labeled with [α-32 P]-ATP with a T4 polynucleotide kinase (Promega) according to the manufacturer's instructions. H460 crude nuclear extract preparation and EMSA were performed as previously described. 19 Briefly, 5 ug of purified nuclear protein extracts were incubated in 20-µl reaction mixtures (20 mM HEPES, pH 8.4; 100 mM KCl; 20% glycerol; 0.1 mM EDTA; 50 ng/ml poly dA-dT; 0.05% NP-40; 1 mg of bovine serum albumin, BSA) at room temperature for 10 min prior to addition of 0.2 ng of radiolabeled oligonucleotide probe. Doses of wild-or mutant-type RARE consensus oligomer (Promega) were added for competition assays. After 20 min of room temperature incubation, samples were separated on 5% acrylamide gels in 0.5X Tris-borate-EDTA buffer. For EMSA supershift studies, 1 ug of polyclonal RAR-β or RXR-β antibodies (Santa Cruz Biotechnology) or, as a control, polyclonal HA antibody (Santa Cruz Biotechnology) were added for 30 min of incubation following the standard binding reaction. Gels were transferred, dried, and exposed to Hyperfilm ECL (Amersham Pharmacia Biotech).
Statistical analysis. For colony formation assay, MannWhitney U test was used to examine the differences in colony numbers between treatment groups. Comparisons of relative levels of luciferase activity among the different transfections were conducted using Kruskal-Wallis H test, followed by Mann-Whitney U test for comparison of relative values between groups. All statistical tests were two sided. p < 0.05 was considered statistically significant.
RESULTS
9cRA increases IGFBP-3 and RAR-β expression. First, to investigate the effect of 9cRA on the anchorage dependent growth of NSCLC cells, we treated NSCLC cells with indicated dose of 9cRA for 24 hr to 48 hr and performed MTT assay. 9cRA did not influence on the proliferation of A549 cells and H1299 cells, whereas inhibited proliferation in H596 and H460 cells (representative data are shown in Fig. 1 ). Figures 2A and B showed that treatment of 500 nM 9cRA inhibited the anchorage-independent growth of H460 NSCLC cells. For controls, 19 ± 2.1 (mean ± SE of four wells) colonies per field were counted compared with 8 ± 0.6 colonies per field counted in 9cRA treated wells (Fig. 2B) . Compared with control cells, treatment of 500 nM 9cRA results in 59.7% inhibition of colony formation ( Fig. 2B ; p < 0.046, Mann-Whitney U test).
To elucidate whether 9cRA is involved in the regulation of IGFBP-3 gene expression, we examined the effect of 9cRA on expression of the IGFBP-3 gene protein in vitro using H460 NSCLC cells cultured at various concentrations and times. As shown in Figure 3A , 9cRA increased IGFBP-3 
Reverse-transcribed mRNA was obtained from cells following the indicated conditions, and the results of subsequent PCR are shown in Figure 3B . High 9cRA concentration in the culture medium consistently induced an increase in IGFBP-3 mRNA. 9cRA also increased RAR-β protein and RAR-β mRNA levels at similar concentrations and times ( Fig. 3A and B) . The 9cRA-mediated induction suggests the involvement of RAR/RXR in IGFBP-3 gene activation, although analysis of the 9cRA effects does not allow discrimination between the relative involvement of RAR and RXR receptors in the activation of IGFBP-3 expression. To elucidate whether RARs play a role in IGFBP-3 gene expression, the synthetic RAR-specific agonist TTNPB was used. As shown in Figure 3C , TTNPB increased IGFBP-3 protein expression in a dose-dependent manner. At the lower concentration (0.1 to 10 nM), this effect was three orders of magnitude higher than those observed with 9cRA.
9cRA increases IGFBP-3 gene expression at the transcriptional level. To investigate the underlying mechanisms in which 9cRA increases IGFBP-3 gene expression, H1299 NSCLC cells were transiently transfected with a pGL2 luciferase reporter vector, driven by the wild-type IGFBP-3 promoter and its serial deletion mutants ( Fig. 4A and B) , and then treated with 9cRA. Selection for H1299 cells was based on a previous experiment that showed these cells to have lower levels of endogenous RAR-β and high transfection efficiency compared to other NSCLC cell lines. 20 As shown in Figure 5 , pGL2-∆862 exhibited a 2.5-fold induction of promoter activity by 9cRA. When a unilateral deletion construct carrying the -534 to -64 region of the IGFBP-3 promoter (pGL2-∆1393) was introduced, the inductive effect of 9cRA was similar to that of pGL2-∆862, whereas further deletion of the promoter region to -445 bp (pGL2-∆1482) abolished the inductive effect of 9cRA. These results indicate that 9cRA acts on IGFBP-3 expression at the transcriptional level and further suggest the presence of a retinoid responsive region between -534 and -445 in the proximal IGFBP-3 promoter.
9cRA activates IGFBP-3 promoter activity via RAR-β. In order to determine those transcription factors critical for 9cRA-induced IGFBP-3 gene expression, H460 cells were transfected with either siRNA for RAR-β or a RAR-β expression vector under the influence of 500 nM 9cRA or the vehicle for 48 hr. Treatment with siRNA for RAR-β decreased IGFBP-3 expression, while the RAR-β expression vector potentiated 9cRA inducement of IGFBP-3. Transfection with the RAR-β expression vector in the absence of 9cRA also induced IGFBP-3, although not at a level comparable to that for the combined treatment with 9cRA and the RAR-β expression vector (Fig. 6A) .
To further elucidate RAR-β involvement in IGFBP-3 gene activation, pGL2-∆1393 containing a putative RARE within the IGFBP-3 gene promoter (-534 to -445) was transfected into H1299 NSCLC cells. These cells were tested under the effects of siRNA for RAR-β and a RAR-β expression vector plus 9cRA (Fig. 6B) . IGFBP-3 promoter activity was enhanced when cells were cotransfected with RAR-β and decreased with siRNA for RAR-β. In contrast, 9cRA in the presence of either siRNA resulted in marginal stimulation of IGFBP-3 promoter activity. This approximately 1.9-kb portion of the human IGFBP-3 promoter also includes a cluster of 11 p53 sites, five Yin and Yang-1 (YY1) sites, a GC-rich/Sp-1 site, and two consensus AP2 sites. The DR-8 RARE is deleted in pGL2-∆1482, as is the entire DR-8 RARE in pGL2-∆1393 (B). Numbering of plasmid follows the designation of Walker et al. 21 9cRA Induces IGFBP-3 via DR-8 RARE Taken together, these data demonstrate the involvement of RAR-β in the 9cRA-induced transactivation of the IGFBP-3 gene.
Identification of retinoid responsive element in IGFBP-3 promoter. Sequence analysis of the IGFBP-3 promoter indicated a putative retinoid responsive element (RARE) composed of a DR-8 sequence (two directlyrepeated TGACCT motifs separated by eight nucleotides; GGGTAA gggcggcgGGGTCA, nucleotides -484 to -465 upstream of the transcription start site) (Fig. 7A) . Owing to data in the previous section suggesting involvement of RAR-β in IGFBP-3 gene transactivation, we suppose this putative responsive element to be a RARE. To determine whether this element mediates the retinoid response of the IGFBP-3 gene, three modified IGFBP-3 promoter plasmid constructs were transfected into H1299 NSCLC with 9cRA. The first construct corresponded to pGL2-∆1393 of the IGFBP-3 promoter mutated to include the 5' GGGTCA motif of the putative RARE [pGL2-∆1393(F)]. When compared to the wild-type construct (pGL2-∆1393), mutation of this element in the RARE sequence led to a 12% reduction in the 9cRA inductive effect. In the second construct, mutation in the 3' motif of the putative RARE [pGL2-∆1393(R)] of the promoter also decreased 9cRA-mediated induction (41.1%). In the third construct, mutations introduced in the GGGTCA-like motif [pGL2-∆1393(B)] of the IGFBP-3 promoter further abolished 9cRA-mediated induction (70.5%; Fig. 7B ). Our data suggest that the putative DR-8 RARE, located from -484 to -465 from the mRNA start site, participates in 9cRA-induced IGFBP-3 expression.
To further investigate the involvement of synthetic retinoic acids in the nuclear translocation of RAR-β and RXR-β, we performed Western blot analysis with a nuclear extract of H460 cells treated with the indicated doses of 9cRA, 13cRA, and TTNPB. Very low induction of RXR-β expression was observed in nuclear extracts from the synthetic retinoic acid derivatives treatment group, whereas RAR-β was strongly induced by 9cRA and 13cRA treatment (Fig. 8A) .
Gel shift analysis was performed, showing the RARE to be an essential region for 9cRA-induced IGFBP-3 promoter activity in H460 NSCLC cells. For this study, we designed a 28-mer oligonucleotide (-488 to -461; WT) spanning the putative RARE in the IGFBP-3 promoter. When the nuclear extract from H460 cells was used, a DNA:protein complex was formed (Fig. 8B) . Specificity of binding was verified by competition assays; in which each complex was successfully out-competed by increasing concentrations of unlabeled wild-type RARE consensus oligonucleotides (S.C.). Complexing was not abolished by treatment with unlabeled mutant RARE consensus oligonucleotides (N.C.) (Fig. 8B) . We then used polyclonal antibodies raised against RAR-β or RXR-β to demonstrate that complexes indeed contained RAR-β. RAR-β antibody (Fig. 8C, lanes 2 ), but not a RXR-β and a control (anti-HA) antibodies (Fig. 8C, lane 3 and 4) , led to disappearance of the complex.
DISCUSSION
With the advent of novel targeted agents such as COX-2 inhibitors, farnesyl transferase inhibitors, and epidermal growth factor receptor tyrosine kinase inhibitors, there has been a push to consider molecular targeted approaches to NSCLC and the development of appropriate surrogate markers for chemoprevention. Despite substantial advances in chemoprevention of breast, colon, bladder, and head/neck cancers, the prevention of lung cancer is still a distant goal. This is in part due to a lack of appropriate surrogate markers suitable for long-term follow-up care. RAR-β, regarded as a tumor suppressor in upper aerodigestive tract cancer, is one of the frequently-used surrogate markers in chemoprevention trials. One recent large-scale chemopreventive trial sought to reverse detectable squamous metaplasia in the bronchial epithelium of former heavy smokers with 9cRA or 13cRA plus α-tocopherol. The study showed that administration of 9cRA reduced the percentage of subjects with detectable squamous metaplasia and led to a statistically significant increase in RAR-β Figure 5 . Luciferase assay of serial deletion mutants of IGFBP-3 promoter with or without treatment of 9cRA. 9cRA treatment induces IGFBP-3 promoter activity in the pGL2-∆1393 reporter vector, which contains a putative RARE. pGL2-∆ 1482 and -∆1600, in which the 5' element of the putative RARE and the entire putative RARE is deleted respectively, revealed a blunted response to 9cRA. Each experiment was repeated at least three times with identical results. RLU, relative luciferase activity. Figure 6 . Treatment with siRNA for RAR-β decreased 9cRA induction of IGFBP-3; siRNA for RAR-β expression vector potentiated this induction. H460 NSCLC cells were treated with siRNA for RAR-β or a RAR-β expression vector under the influence of 500 nM 9cRA or the vehicle for 48 hr. Whole cell extracts were prepared and analyzed by immunoblot (A). Promoter activity of pGL2-∆1393 was measured after treatment with siRNA for RAR-β or the RAR-β expression vector under the influence of 500 nM 9cRA or vehicle (B). Each experiment was repeated at least three times with identical results. RLU, relative luciferase activity.
9cRA Induces IGFBP-3 via DR-8 RARE expression in the biopsy site. Although RAR-β was effectively upregulated by 9cRA in the bronchial epithelium of former smokers, data implicating maintenance of RAR-β intratumoraly in stage I NSCLC in individuals with a poorer prognosis 3 has shed some doubt on these results. 1 Consecutive reports that elevated IGF-1 and decreased IGFBP-3 in circulation are related to the development of various solid cancers, however, not only bolster IGFBP-3 as a good candidate for surrogate marker but also urge the development of effective ways to up-regulate IGFBP-3.
Here, we demonstrated that the expression of IGFBP-3 in NSCLC cells was induced by the pan-retinoic acid receptor agonist, 9cRA, and that administration of this agent decreased frequency of metaplasia in the bronchial epithelium of former heavy smokers. 2 Induction of IGFBP-3 expression by 9cRA occurs at the transcriptional level, as measured by semi-quantitative RT-PCR. Concurrence of semi-quantitative RT-PCR and Western blot in the expression of IGFBP-3 and RAR-β indicated that 9cRA activates IGFBP-3 gene transcription, supporting the previous findings that a major consensus sequence for retinoic acid may be present in the promoter region of the IGFBP-3 gene. 24 By using a RAR-selective agonist (TTNPB), we demonstrated that RAR-β expression was induced by 9cRA through a RAR-dependent signaling pathway and that RAR-β induction was correlated with IGFBP-3 induction. Further, expression of IGFBP-3 is mediated by RAR-β, as blocking of RAR-β expression by siRNA for RAR-β diminished expression of IGFBP-3. When H1299 cells were transfected with cDNA encoding RAR-β, the promoter activity of IGFBP-3 was increased; it was further augmented in the presence of 9cRA. Transfection of H460 cells with siRNA for RAR-β not only inhibited 9cRA-induced IGFBP-3 expression, but also IGFBP-3 promoter activity, indicating that RAR-β is directly involved in the mediation of IGFBP-3 induction by 9cRA. A connection between IGFBP-3 and RAR-β defines the signal intersection between the retinoid and IGF systems in cell growth regulation and suggests why the loss of RAR-β might be critical in NSCLC carcinogenesis and progression.
Several regulatory elements-a cluster of 11 p53 consensus binding sites; five consensus Yin and Yang-1 (YY1) sites; a sequence cluster comprised of a GC-rich/ Sp1 site, AP-2 site overlapping a GA-box, and p300 DNA binding site-are found in the promoter of IGFBP-3. 21 Earlier work using rat IGFBP-3 promoter identified the major consensus sequences that could be activated by retinoic acid as an AP-2 and an Oct site, which locate from -78 to -71 and at -612, respectively, relative to the transcription start site. There are, however, minor differences between human and rat IGFBP-3 promoter sequences. Between the human and rat IGFBP-3 promoters, there is 65% sequence conservation within 1.2 kb of the promoter, and the rat IGFBP-3 promoter lacks a putative RARE in the 5'-untranslated flanking region. 24 Computer-based simulation using the transcription element search system (TESS; http://www.cbil.
upenn.edu/tess) algorithm and our experiment using serial deletion mutants cloned into the pGL2-reporter vector showed that a RARE consisting of two half-sites arranged as a direct repeat with an 8-bp spacer (DR-8) is located from -484 to -465 relative to the translation start site. This DR-8 in the human IGFBP-3 promoter is different from the canonical RARE, represented by DR-1 to DR-5. 25 The classical DR-5 elements are found in the promoters of the RAR-β itself 26 and several Hox and HNF genes. 27,28 DR-8 motifs previously identified in the promoter lesion of human H1 histone and the RAR-β gene interact with thyroid hormone receptors (TRs), RARs and RXR, COUP-TF, and v-erbA in a ligand-dependent manner. 29, 30 In a study using the DR-8 sequence in the human H1 promoter, COUP-TF, which usually represses RAREs, enhanced transcriptional activation through the DR-8. In constrast, v-erbA completely repressed TR-RXR induction of the H1 gene. 29 The pattern of site selectivity is based on the spacing of DRs(1-5 rule) and polarity of RAR-RXR complexes. 31, 32 Among the canonical RAREs, RAR-RXR complex have preference for DR-1, DR-2, and DR-5 RARE. 33 The facts that expression of RXR-β is suppressed in a large percentage of NSCLC, 34 its expression is relatively lower than that of other type of RXRs, 35 and as shown in (Fig. 8C) , nuclear translocation of RXR-β is not influenced by 9cRA might be implicated in failure of supershift by RXR-β antibody. Further studies may be needed to identify appropriate partners of RAR-β in heterodimeric complex formation for binding of DR-8 RARE in IGFBP-3 promoter.
Our study demonstrates that reporter constructs containing DR-8 allowed a several-fold induction of IGFBP-3 promoter activity by 9cRA in the presence of RAR-β. Also, RAR-β binding to the DR-8 was enhanced in the presence of 9cRA. Several signaling pathways that play important roles during differentiation and cell proliferation thus influence the rate of IGFBP-3 transcription through a DR-8 response element in its promoter. Mutational analysis suggests that this site is functionally a DR-8 element for retinoic acid derivatives. We further demonstrated binding of RAR-β to the DR-8 element in electrophoretic mobility shift and competition assays between the RAR consensus sequence and another sequence bound by RAR-β.
Our experiments show that RAR-β is involved in the growth inhibitory activity of 9cRA via mediation of the induction of IGFBP-3 expression. Because both IGFBP-3 and RAR-β expression levels inversely correlate with cell proliferation and are regarded as putative tumor suppressor genes in NSCLC, our data suggest that retinoic acids such as 9cRA can influence cell proliferation via regulation of the DR-8 element. By elucidating the linkage mechanism between IGFBP-3 and RAR-β, our experiments have pinpointed an intersection between the retinoid and IGF systems. This information also expands knowledge of the downstream effectors of RAR-β and suggests how RAR-β might act as a tumor suppressor.
